Phase IB/II of CPX-351 for Relapse Prevention in AML
Phase IB/II of CPX-351 for Relapse Prevention in AML
Recruiting · NCT04990102 · Registry updated 2026-03-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase IB/II of CPX-351 for Relapse Prevention in AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-03-23 | NCT04990102 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Georgetown University | 73 |
| Jazz Pharmaceuticals | 60 |
| National Heart, Lung, and Blood Institute (NHLBI) | 791 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Georgetown Lombardi Comprehensive Cancer Center | Washington D.C. | United States | 14 |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | United States | 37 |
| University of Pennsylvania | Philadelphia | United States | 507 |